Zhiran Medical

BCIFlex Medical Technology has begun a clinical trial in China evaluating the safety and efficacy of an implantable wireless brain-computer interface in patients left tetraplegic by spinal cord injury. The trial is registered on ClinicalTrials.gov as NCT07784088 and is recruiting. The sponsor is a Chinese device maker headquartered in the Haidian district of Beijing with an office in Shanghai, working on invasive ultra-thin flexible electrodes; its products include digital EEG systems and stereo-EEG depth electrodes.

China's brain-computer interface sector recorded 47 funding rounds in the first half of 2026, 38 of them disclosing terms for a combined RMB 5.38 billion (approx. $750 million). A broader tally used by Chinese financial media puts the total at 64 deals and roughly RMB 7.25 billion (approx. $1 billion). Either figure is more than double the whole of 2025 (49 deals, RMB 2.72 billion) at a comparable deal count. The record lists every deal by month — company, technical approach, round, amount, investors — and identifies three structural patterns: ultrasound and non-invasive approaches moving quickly into a field long defined by implants, Big Tech and municipal state funds entering at the same time, and nearly half of all transactions still sitting at angel or seed stage.